Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cabaletta Bio Inc
(NQ:
CABA
)
1.870
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
70
Open
1.870
Bid (Size)
1.800 (2)
Ask (Size)
1.950 (119)
Prev. Close
1.870
Today's Range
1.870 - 1.870
52wk Range
1.760 - 26.35
Shares Outstanding
31,355,723
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
November 18, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Performance
YTD
-91.56%
-91.56%
1 Month
-56.41%
-56.41%
3 Month
-67.76%
-67.76%
6 Month
-83.32%
-83.32%
1 Year
-89.86%
-89.86%
More News
Read More
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 06, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
September 25, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Recap: Cabaletta Bio Q4 Earnings
March 21, 2024
Via
Benzinga
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
August 28, 2024
From
Cabaletta Bio
Via
GlobeNewswire
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q2 2024
August 08, 2024
Via
InvestorPlace
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
July 19, 2024
Via
Benzinga
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
July 02, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 21, 2024
Via
Benzinga
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
June 21, 2024
Via
Benzinga
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 18, 2024
Via
Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
June 14, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Cabaletta Bio
Via
GlobeNewswire
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024
May 15, 2024
Via
InvestorPlace
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
May 15, 2024
Via
Benzinga
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 15, 2024
Via
Benzinga
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024
From
Cabaletta Bio
Via
GlobeNewswire
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023
March 21, 2024
Via
InvestorPlace
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
March 20, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
March 06, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.